AnTolRx, Inc.
One Kendall Square
Building 1400 West, Suite 14303
Cambridge
Massachusetts
02139
United States
Tel: 617-945-8468
Website: http://antolrx.com/
Email: jessica.kenison@antolrx.com
About AnTolRx, Inc.
At AnTolRx, we are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Our proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.YEAR FOUNDED:
2016
LEADERSHIP:
Founder and CEO: Mark Carthy
Scientific Founder: Francisco J Quintana, PhD
Member BoD: Satish Jindal, PhD
Scientific Consultant: Vincent Stanton Jr.
Senior Scientist: Jessica Kenison-White
CLINICAL
Please click here for AnTolRx's Pipeline.
2 articles about AnTolRx, Inc.
-
AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes
3/5/2019
Pfizer has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx's Type 1 diabetes research program.
-
AnTolRx Announces Series A Equity Funding From Pfizer, Juvenile Diabetes Research Foundation And Orion Equity Partners To Develop Targeted Nanoparticle Tolerance Therapeutics
9/8/2016